Sudarshan Sukhani of s2analytics.com is of the view that one can sell PNB and HPCL and can buy Hexaware, Infosys, Jubilant Foodworks and Sun Pharma.
CICIdirect expects weak results from Sun Pharma due to continued pricing pressure in Taro portfolio and FDA issues at Halol plant and also Lupin due to competition in generic Fortamet and Glumetza, and Glenmark Pharma due to weak US growth on high base with Zetia exclusivity.
VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities is of the view that one can buy Federal Bank 115 Call, RBL Bank 550 Call and Sun Pharmaceutical Industries 660 Call.
The market breadth was in favour of the advances on Monday morning with 1161 stocks advancing as against 467 declines while 386 remained unchanged. On the other hand, 1633 stocks advanced and 676 stocks declined while 88 remained unchanged on the BSE.
"The US Food and Drug Administration (USFDA) has accepted a new drug application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution)," Sun Pharmaceutical Industries said in a BSE filing.
Riomet, which is an oral diabetes medicine that helps control blood sugar level, was found to be contaminated.
Centrum recommended hold rating on Sun Pharma with a target price of Rs 490 in its research report dated November 18, 2017.
Use of contaminated Riomet potentially could result in a risk of infection, especially in the immunocompromised patient.
Sun Pharmaceutical Industries and Cadila Healthcare second quarter results were the major result announcements this week.
The company reported net profit of Rs 2235 crore in the same period of previous year. Revenues declined 19.5 percent to Rs 6650 crore compared to Rs 8260 crore in the year ago period.
An official statement issued by Attorney General (AG) of Washington State, Bob Ferguson, yesterday said AGs of 45 other states, along with him, approached a federal court seeking to expand the pending complaint, increase the number of drug companies under probe to 18 from 6 and the number of affected drugs to 15 from 2.
Forty-six US state attorneys general will seek to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday, including Novartis AG's generic unit Sandoz and India-based Sun Pharmaceutical Industries Ltd.
Dadra is the company’s second largest USFDA-approved plant after Halol with several pending generic filings. Analysts estimate the Dadra formulation plant to generate USD 250 million in annual sales.
Mitessh Thakkar of mitesshthakkar.com is of the view that one can buy Sun Pharma and Escorts and can sell Indiabulls Real Estate, United Spirits and Strides Shasun.
Jewellery stocks, the likes of PC Jeweller and Titan Company which were up between 3-4 percent while ICICI Bank was the top gainer in the Nifty50 Index while SPARC plunged 11 percent intraday.
Mitessh Thakkar of miteshthacker.com recommends buying Sun Pharma and Escorts.
Ashwani Gujral of ashwanigujral.com advises holding Future Consumer with a stop loss at Rs 50.
"We have identified the speciality segment as one such driver which can help us transition up the value chain," he added.
Basant Maheshwari of Basant Maheshwari Wealth is of the view that pharma should be looked at but advises starting from the top notch companies, the bluechips.
According to Mitessh Thakkar of mitesshthakkar.com, one can sell Apollo Hospitals, Can Fin Home and ICICI Prudential Life and can buy Reliance Defence and Sun Pharma.
Pharma stocks like Divis Labs, Lupin, Aurobindo Pharma, Strides Shasun, Wockhrdt and Sun Pharma will get astrological support, says Satish Gupta of astrostocktips.
Prakash Gaba of prakashgaba.com is of the view that HDFC Bank can climb to Rs 1860 while Sun Pharma may test Rs 530.
Ashwani Gujral of ashwanigujral.com recommends selling Idea Cellular, Sun Pharma and Interglobe Aviation and advises buy Titan Company and UltraTech Cement.
The company is also entering into the third and the most important year of integration of Ranbaxy with the company.